Valuation: Lexicon Pharmaceuticals, Inc.

Market Cap 793M 719M 665M 600M 1.13B 74.05B 1.18B 8.01B 3.17B 39.96B 2.97B 2.91B 126B P/E 2026 *
-11.1x
P/E 2027 * -8.81x
Enterprise Value 793M 719M 665M 600M 1.13B 74.05B 1.18B 8.01B 3.17B 39.96B 2.97B 2.91B 126B EV / Sales 2026 *
21.2x
EV / Sales 2027 * 44.4x
Free-Float
98.04%
Yield 2026 *
-
Yield 2027 * -
11-09 Lexicon Pharmaceuticals, Inc. Announces Research Collaboration with Ichan School of Medicine At Mount Sinai and Penn Cardiovascular Institute CI
11-07 Lexicon Pharmaceuticals, Inc., Q3 2026 Earnings Call, Nov 05, 2026
11-05 Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
10-23 Lexicon Pharmaceuticals, Inc. Provides Update On Baseline Patient Characteristics For Pivotal Phase 3 SONATA-HCM Study Of Sotagliflozin In Symptomatic Hypertrophic Cardiomyopathy CI
10-23 Lexicon Says Sotagliflozin Trial Exceeds Enrollment Goal With 542 Patients MT
09-28 Lexicon Pharmaceuticals Shares Rise After Cantor Fitzgerald Initiates With Overweight Rating MT
09-28 Cantor Fitzgerald Initiates Lexicon Pharmaceuticals at Overweight With $8 Price Target MT
09-09 Lexicon Pharmaceuticals, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 11:20 AM
08-31 Lexicon Pharmaceuticals Announces Results from Post Hoc Soloist-Whf Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure CI
08-24 Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk DJ
08-24 Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851 MT
08-06 Lexicon Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026
08-06 Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
1 day+1.71%
1 week-4.30%
Current month+25.35%
1 month+17.11%
3 months-23.93%
6 months-20.18%
Current year+54.78%
1 week 1.72
Extreme 1.715
1.89
1 month 1.36
Extreme 1.365
1.97
Current year 1.1
Extreme 1.1
2.68
1 year 1.1
Extreme 1.1
2.68
3 years 0.28
Extreme 0.2836
3.73
5 years 0.28
Extreme 0.2836
5.22
10 years 0.28
Extreme 0.2836
18
Manager TitleAgeSince
Chief Executive Officer 56 07/07/2024
Director of Finance/CFO 59 01/01/2025
Chief Tech/Sci/R&D Officer - 31/01/2025
Director TitleAgeSince
Chairman 83 31/12/2004
Chairman 71 26/02/2012
Director/Board Member 67 27/08/2007
Date Insider Type Main position Quantity % Market Cap. Importance
03/06/26 Exercice

Director

178,624 0.0402%
03/06/26 Exercice

Director

178,624 0.0402%
03/06/26 Exercice

Director

178,624 0.0402%
Change 5-day change 1-year change 3-year change Capi.($)
+1.71%-4.30%+21.92%+58.93% 793M
+1.15%-2.81%+55.79%+71.12% 66.37B
-2.64%-1.13%+7.82%+88.90% 58.86B
-1.07%+0.30%+22.91%+86.76% 55.22B
+0.48%-2.53%+9.73%+121.14% 47.21B
-2.69%-6.38%+19.19%+25.79% 42.45B
-0.70%+4.93%+17.77%+45.03% 36.44B
-2.50%-15.73%+135.31%+662.73% 35.19B
-0.77%-2.21%+77.27%+57.96% 32.66B
-0.83%+1.98%-38.27%+390.98% 26.73B
Average -0.79%-2.44%+32.94%+160.93% 40B
Weighted average by Cap. -0.97%-2.18%+33.91%+146.57%

Financials

2026 *2027 *
Net sales 37.41M 33.96M 31.37M 28.3M 53.43M 3.5B 55.47M 378M 150M 1.89B 140M 137M 5.96B 17.87M 16.22M 14.98M 13.52M 25.52M 1.67B 26.5M 181M 71.41M 901M 67.04M 65.63M 2.85B
Net income -69.97M -63.52M -58.68M -52.94M -99.94M -6.54B -104M -707M -280M -3.53B -263M -257M -11.15B -94.81M -86.07M -79.5M -71.72M -135M -8.86B -141M -958M -379M -4.78B -356M -348M -15.1B
Net Debt - -
Projected Income Statement - Annual - Lexicon Pharmaceuticals, Inc.
Logo Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Employees
81
Date Price Change Volume
17/11/26 US$1.780 +1.71% 2,416,623
16/11/26 US$1.750 -2.23% 1,482,135
13/11/26 US$1.790 -1.65% 1,893,364
12/11/26 US$1.820 -2.67% 1,685,718
11/11/26 US$1.870 +0.54% 3,086,488
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Lexicon Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.780USD
Average target price
4.515USD
Spread / Average Target
+153.65%
  1. Stock Market
  2. Stocks
  3. LXRX Stock